SU959784A1 - Method of restoring antiaggregation activity of vessel walls - Google Patents
Method of restoring antiaggregation activity of vessel walls Download PDFInfo
- Publication number
- SU959784A1 SU959784A1 SU813290200A SU3290200A SU959784A1 SU 959784 A1 SU959784 A1 SU 959784A1 SU 813290200 A SU813290200 A SU 813290200A SU 3290200 A SU3290200 A SU 3290200A SU 959784 A1 SU959784 A1 SU 959784A1
- Authority
- SU
- USSR - Soviet Union
- Prior art keywords
- activity
- restoring
- antiaggregation
- adrenaline
- vessel walls
- Prior art date
Links
- 230000002744 anti-aggregatory effect Effects 0.000 title claims description 16
- 230000000694 effects Effects 0.000 title claims description 13
- 238000000034 method Methods 0.000 title claims description 8
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Diphosphoinositol tetrakisphosphate Chemical compound OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 claims description 10
- 230000002792 vascular Effects 0.000 claims description 7
- 241001465754 Metazoa Species 0.000 claims description 6
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 claims description 6
- 229960002768 dipyridamole Drugs 0.000 claims description 6
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 5
- 235000013922 glutamic acid Nutrition 0.000 claims description 5
- 239000004220 glutamic acid Substances 0.000 claims description 5
- 210000003038 endothelium Anatomy 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims 1
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 20
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 210000000709 aorta Anatomy 0.000 description 2
- 210000000702 aorta abdominal Anatomy 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- -1 C4-8 mg / g) Chemical compound 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229940105631 nembutal Drugs 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 210000004623 platelet-rich plasma Anatomy 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
Изобретение относитс к экспериментальной биологии и медицине и может быть использовано дл изучени нормальной и патологической физиологии сосудистой стенки и возможных путей изменений ее состо ни .The invention relates to experimental biology and medicine and can be used to study the normal and pathological physiology of the vascular wall and possible ways of changing its state.
Известно, что незначительное понлшение антиагрегационного действи стенки сосуда отмечаетс под вли нием никотиновой кислоты.It is known that a slight decrease in the anti-aggregation effect of the vessel wall is observed under the influence of nicotinic acid.
Однако известный способ не позвол ет устранить ингибиругацую функцию сосудистой стенки и активировать исходную антиагрерационную активность эндотели .However, the known method does not allow to eliminate the inhibitory function of the vascular wall and activate the initial antiaggregation activity of the endothelium.
Целью изобретени вл етс устранение ингибирующей функции сосудистой стенки и активаци антиагрегационной активности , эндотели .The aim of the invention is to eliminate the inhibitory function of the vascular wall and activate anti-aggregation activity, the endothelium.
Данна цель достигаетс тем, что в организм ввод т последовательно фитин, глютаминовую кислоту пероргшьно , а затем дипиридамол внутрйвён но..This goal is achieved by the fact that phytin, glutamic acid is administered sequentially into the body, and then dipyridamole is intravenously.
, В экспериментах на крысах в услови х экспериментального снижени а.нтиагрегационных свойств эндотели сосудов под вли нием адреналина . (0,04 мг/200 г) введение фитина ,С4-8 мг/г), глютаминовой кислоты, In experiments on rats under conditions of experimental decrease in an.Antigagregative properties of vascular endothelium under the influence of adrenaline. (0.04 mg / 200 g) administration of phytin, C4-8 mg / g), glutamic acid
(10-16 мг/кг) перорально, а затем дипиридамола ( 0,2- 0,6 мг/кг ) предотвращало торможение антиагрегационной активности, вызываемое адреналином. На фоне снижени антиагрегационной активности эндотели под вли нием адреналина предложенный способ восстанавливал антиагрегационный потенциал стенки сосуда.(10–16 mg / kg) orally and then dipyridamole (0.2–0.6 mg / kg) prevented the inhibition of antiaggregation activity caused by adrenaline. Against the background of a decrease in the antiaggregation activity of the endothelium under the influence of adrenaline, the proposed method restored the antiaggregation potential of the vessel wall.
10ten
Предложенный способ восстанавливает антиагрегационную активность луЗше, чем ингибитор тромбоксансиптетазы никотинова кислота и ее препарат компламин,а также изолировано 5 примененный дипиридамол. .The proposed method restores the anti-aggregation activity of LuZshe than the thromboxanesiptetase inhibitor nicotinic acid and its preparation complamine, as well as the isolated 5 applied dipyridamole. .
Результаты сравнительного исследовани действи различных лекарственных веществ на восстановление антиагрегационной активности сосудис20 той стенки, поврежденной введением адреналина (0,04 мг/200 г), приведены в таблице.The results of a comparative study of the effect of various medicinal substances on the restoration of the antiaggregatory activity of the vascular wall of the wall damaged by the administration of adrenaline (0.04 mg / 200 g) are listed in the table.
Пример..Первой группе животных (крыс) ввод т адреналин .25 внутривенно из расчета 0,004 мг/200 Г, второй - перорально фитин 7 мг/кг/ глютаминовую кислоту 14 мг/кг, а через 30 мин внутривенно дипиридамол в дозе 0,42 мг/кг. Через 30 мин . 30 второй группе животных ввод т г1дреНсшин в той же дозировке, что и жи вотным первой группы. Под нембуталовым наркозом извлекают брюшной отдел аорты. Вырезают участок брюшной аорты выше бифуркапий , пропаласкивают в трис-буфере (рН 7,5) при температуре так цего льда. Перед исследованием аорту очищают от окружающей соединительной ткани, разрезают вдоль и нарезают полоски длиной 5-7 мм и массой 5-7 мг. Эти полоски помешают в кювету агрегометра, содержащую 0,5 мл обогащенной тромбоцитами плазмы в концентрации 3-4x10 клеток в 1 л на 3 мин. После инкубации при температуре 20-22С кусочки вынимают и в кювете определ ют агрегационную способность тромбоцитов , вызванную АДФ (10 М). Инку баци обогащенной тромбоцитами сте сосуда приводит к торможению агрег ции по сравнению с контролем, Антиагрегационна активность- ст ки- аорты здоровых животных в среднем составила 31,5-0,7%, после вве ни адреналина - 15,5 - 0,72%. На не применени предложенного cijoco6 антиагрегационна активность стенк аорты составила после введени адреналина 46,1-0,3%. Следовательно, предложенный способ предупреждает снижение антиагрегационной активности стенки аорты под вли нием адреналина. П р и м е р 2. Крысам внутривенно ввод т адреналин (0,004 мг/200 г). Затем через 30 мин перорально ввод т фитин.7 мг/кг, глютаминовую кислоту 14 мг/кг и ..еще через 30 мин внутривенно дипиридамол 0,42 мг/кг. Контрольной группе животных вводили только адренсшин. В исходном состо ний антиагрегационна активность стенки аорты составл ла 31,5-0,7%, после введени адреналина - 15,5-0,72%, после применени предложенного 48-0,7%. Следовательно, применение за вл емого способа способствует восстановлению антиагрегационной активности стенки аорты. Предложенный способ может найти применение в медико-биологических экспериментах, в частности дл изучени механизмов реакций сосудистой стенки на различные стрессорные факторы и др.Example..The first group of animals (rats) was injected with adrenaline .25 intravenously at the rate of 0.004 mg / 200 G, the second - oral phytin 7 mg / kg / glutamic acid 14 mg / kg, and after 30 min, intravenous dipyridamole at a dose of 0.42 mg / kg After 30 minutes 30, the second group of animals is injected in the same dosage as the animals of the first group. Under Nembutal anesthesia, the abdominal aorta is removed. A portion of the abdominal aorta is cut out above the bifurcapium, and drained in Tris buffer (pH 7.5) at the temperature of the ice. Before the examination, the aorta is cleaned of surrounding connective tissue, cut along and cut into strips 5-7 mm long and weighing 5-7 mg. These strips are placed in an aggregometer cuvette containing 0.5 ml of platelet-rich plasma at a concentration of 3-4x10 cells per liter for 3 minutes. After incubation at a temperature of 20-22 ° C, the pieces are removed and the aggregation capacity of the platelets, caused by ADP (10 M), is determined in the cuvette. Incubation of platelet-rich stems leads to inhibition of aggregation as compared to control, the antiaggregation activity of the lives of healthy animals averaged 31.5-0.7%, after injection of adrenaline - 15.5 - 0.72% . After not administering adrenaline, 46.0-0.3% of antiaggregatory activity of the aorta walls did not apply the proposed cijoco6. Therefore, the proposed method prevents the decrease of the antiaggregation activity of the aortic wall under the influence of adrenaline. Example 2: Adrenaline (0.004 mg / 200 g) was intravenously injected into rats. Then after 30 minutes phytin is administered orally. 7 mg / kg, glutamic acid 14 mg / kg, and more, after 30 minutes, dipyridamole 0.42 mg / kg intravenously. The control group of animals was administered only adrenshin. In the initial state, the antiaggregative activity of the aortic wall was 31.5-0.7%, after administration of adrenaline - 15.5-0.72%, after applying the proposed 48-0.7%. Therefore, the use of the inventive method contributes to the restoration of the antiaggregation activity of the aortic wall. The proposed method can be used in biomedical experiments, in particular, to study the mechanisms of the reaction of the vascular wall to various stress factors, etc.
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SU813290200A SU959784A1 (en) | 1981-06-02 | 1981-06-02 | Method of restoring antiaggregation activity of vessel walls |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SU813290200A SU959784A1 (en) | 1981-06-02 | 1981-06-02 | Method of restoring antiaggregation activity of vessel walls |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SU959784A1 true SU959784A1 (en) | 1982-09-23 |
Family
ID=20958784
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SU813290200A SU959784A1 (en) | 1981-06-02 | 1981-06-02 | Method of restoring antiaggregation activity of vessel walls |
Country Status (1)
| Country | Link |
|---|---|
| SU (1) | SU959784A1 (en) |
-
1981
- 1981-06-02 SU SU813290200A patent/SU959784A1/en active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5025029A (en) | Method for augmenting fetal hemoglobin | |
| EP0217206B1 (en) | Medicament against chronic graft-versus-host diseases, as well as against autoimmune diseases, particularly systemic lupus erythematodes | |
| US5459163A (en) | Medicament to combat autoimmune diseases | |
| KR100230514B1 (en) | Arginine antagonists to inhibit systemic hypotension associated with nitric oxide formation or endothelial induced relaxation factors | |
| PHILIPPART et al. | Reversal of an inborn sphingolipidosis (Fabry's disease) by kidney transplantation | |
| EP0137542B1 (en) | Use of defibrotide in the treatment of states of acute renal insufficiency | |
| Aikawa | Effect of glucose and insulin on magnesium metabolism in rabbits. A study with Mg28. | |
| US5650404A (en) | Therapeutic composition for pancreatitis | |
| US5114916A (en) | Therapeutic agent for the prevention of intraventricular hemorrhage in premature infants | |
| SU1456008A3 (en) | Method of producing acid-additive salts of amidine compounds | |
| Bonta et al. | Anti-inflammatory mechanism of inflamed-tissue factor | |
| US5661188A (en) | Therapeutic uses for sodium 2-mercaptoethanesulphonate (mesna) | |
| SU959784A1 (en) | Method of restoring antiaggregation activity of vessel walls | |
| US3959492A (en) | Method for reducing serum blood cholesterol | |
| EP0278416B1 (en) | Use of human blood coagulation factor xiii for the treatment of ulcerative colitis | |
| UA58565C2 (en) | Cytoflavin injectional drug possessing cytoprotective properties | |
| EP0106812B1 (en) | Pharmaceutical composition containing a fibrinolytic agent and a diffusion factor, useful for the treatment of the myocardium infarction | |
| US4124724A (en) | Crystalline caffeic acid derivatives and compositions and method for treating snakebite | |
| US4022907A (en) | Pharmaceutical compositions containing 1,3-dithiacycloalkylidene malonates | |
| NO803918L (en) | PROCEDURE FOR THE MANUFACTURE OF NEW ESTERS OF ARGININE | |
| US5401725A (en) | Neovascularization inhibition by adenosine-5'-phosphosulfates | |
| Torda et al. | The nature of myasthenia gravis | |
| EP0249401A1 (en) | Antianemic agent | |
| Ino et al. | Effects of FUT-175, a novel synthetic protease inhibitor, on the development of adjuvant arthritis in rats and some biological reactions dependent on complement activation | |
| SU1055515A1 (en) | Method of recovery of antiaggregation activity of vessel walls |